Company intelligence / Profile preview
Endacea, Inc.
Research Triangle Park/Durham area, North Carolina, United Statesendacea.org ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
The lead compound L‑97‑1, a water-soluble, orally bioavailable "best-in-class" A1 AR antagonist, has demonstrated proof-of-concept efficacy as an adjunctive anti-sepsis treatment in animal models of polymicrobial sepsis and endotoxemia. The company also develops a companion diagnostic endotoxin assay to identify patients at risk or suffering from sepsis. No clinical trial phases reported yet; development remains preclinical with strong focus on biodefense and inflammatory conditions[1][2][3][5].
- Therapeutic areas
- ImmunologyPulmonologyInfectious DiseasesNephrology
- Modalities
- Small molecule drugs (A1 adenosine receptor antagonists)Diagnostic assays (endotoxin assay for sepsis detection)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Endacea, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Endacea, Inc..